Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes.
Westra H-J., Martínez-Bonet M., Onengut-Gumuscu S., Lee A., Luo Y., Teslovich N., Worthington J., Martin J., Huizinga T., Klareskog L., Rantapaa-Dahlqvist S., Chen W-M., Quinlan A., Todd JA., Eyre S., Nigrovic PA., Gregersen PK., Rich SS., Raychaudhuri S.
To define potentially causal variants for autoimmune disease, we fine-mapped1,2 76 rheumatoid arthritis (11,475 cases, 15,870 controls)3 and type 1 diabetes loci (9,334 cases, 11,111 controls)4. After sequencing 799 1-kilobase regulatory (H3K4me3) regions within these loci in 568 individuals, we observed accurate imputation for 89% of common variants. We defined credible sets of ≤5 causal variants at 5 rheumatoid arthritis and 10 type 1 diabetes loci. We identified potentially causal missense variants at DNASE1L3, PTPN22, SH2B3, and TYK2, and noncoding variants at MEG3, CD28-CTLA4, and IL2RA. We also identified potential candidate causal variants at SIRPG and TNFAIP3. Using functional assays, we confirmed allele-specific protein binding and differential enhancer activity for three variants: the CD28-CTLA4 rs117701653 SNP, MEG3 rs34552516 indel, and TNFAIP3 rs35926684 indel.